Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025Bleeding Thrombosis and Vascular BiologyOpen Access

PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Retrospective analysis evaluates DOAC safety and efficacy in 31 patients with inherited thrombophilia, suggesting effective long-term management.

Key Points

  • DOACs like rivaroxaban and apixaban proved effective in preventing venous thromboembolism in high-risk patients with inherited thrombophilia.
  • Among 31 patients, DVT recurrence rate was low at 3.2%, indicating potential stability in treatment efficacy over time.
  • Minor bleeding events were observed in 6.4% of patients; however, they were not major and did not require drug adjustments.
  • The study highlights the safety of long-term DOAC use without major hemorrhages, promoting wider application in similar patient cohorts.

Cite This Study

A 2025 study studied this question.

synapsesocial.com/papers/689521f09f4f1c896c42870ahttps://doi.org/10.4081/btvb.2025.300
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study2025
  2. 2CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study2025
  3. 3Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study2025 · 1 citations
  4. 4Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of venous thromboembolism: A systematic review and meta-analysis2025
  5. 5Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran2026